Sign in
Taking people in RussiaPhase 4

Treatment protocol for B-cell non-Hodgkin lymphoma in children and adolescents

Tests different chemotherapy combinations in children and teens with B-cell lymphoma, based on risk.

Key facts

Who runs it
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Where
Moscow, RussiaSee the site
Trial code
Registry title
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Status
Recruiting
Phase
Phase 4
People taking part
300 people, planned
Started
25 May 2022
Expected to end
16 May 2027
Type of study
Interventional, 4 groups
Treatments tested
  • Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
  • Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
  • Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
  • Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
Record updated
26 August 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adolescents with newly diagnosed mature B-cell non-Hodgkin lymphoma, such as Burkitt lymphoma, diffuse large B-cell lymphoma, primary mediastinal lymphoma or primary CNS lymphoma.

Age
0 to 18 years at diagnosis
Sex
All
Disease stage
Burkitt lymphoma, diffuse large B-cell lymphoma, primary mediastinal lymphoma, primary CNS lymphoma or B-cell (Burkitt) acute leukaemia
Earlier treatment
Previous cancer is not allowed.

Main reasons for not taking part

  • Previous cancer
  • Prior organ transplant
  • HIV infection or AIDS, or severe immunodeficiency
  • Allergy to rituximab or to ingredients of the other trial drugs
  • No informed consent from parents or guardians

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age at diagnosis 0 to 18 years
  • The diagnosis of Burkitt's lymphoma, Diffuse large B-cell lymphom, primary mediastinal lymphoma, primary CNS lymphoma, B-cell (Burkitt) AL
  • Informed consent of the patient parents (guardians) to be treated

Who cannot take part

  • previous malignancy, prior organ transplant, HIV infection or AIDS or severe immunodeficiency
  • hypersensitivity to rituximab or to ingredients of other IMPs
  • no informed consent of the patient parents (guardians) to be treated

Where in Russia

  • Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and ImmunologyMoscow, RussiaContact: Yulia AbugovaTaking people

About the trial

What the trial wants to find out

The aim of the trial is to evaluate the molecular characteristics and MDD/MRD of B-NHL in pediatric patients in order to identify on the one hand the very high risk group and to prescribe them more intensive treatment on the other hand to identify those patients who don't need very aggressive therapy. One more study question is to evaluate the role of PET/CT in assessment of the completeness of remission.

Read full original descriptionShow less

The following primary study questions are going to be analyzed:

* the effectiveness (event-free survival) in pediatric patients with very limited mature B-NHL (R1 - stage I and II R) of substituting anthracyclines and vincristine by the rituximab without compromising survival rates. * the effectiveness (event-free survival) in pediatric patients with limited mature B-NHL (R2 - stage I and II NR) of substituting anthracyclines by the rituximab without compromising survival rates. * the effectiveness (event-free survival) in pediatric patients with advanced VHR mature B-NHL (R4 - stages with unfavourable genetics of substituting standard chemotherapy by "second-line" block VICI in order to improve results

Secondary study questions will address

* additional parameters for immune reconstitution, lymphocyte subpopulations, immunoglobulin levels, vaccination titers and infection rates * kinetics of immune reconstitution after treatment

The 4 groups in the trial

  • R1: stage I and IITreatment being tested

    R1: resection status: complete, stage I and II

    Treatment: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate

  • R2: incomplete, stage I and IITreatment being tested

    R2: resection status: incomplete, stage I and II

    Treatment: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine

  • R3: incomplete, stage III and LDH < 2 x ULNTreatment being tested

    R3: resection status: incomplete, stage III and LDH \< 2 x ULN

    Treatment: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine

  • R4: stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +Treatment being tested

    R4: resection status: incomplete, stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +

    Treatment: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)
Plain-language title
Treatment protocol for B-cell non-Hodgkin lymphoma in children and adolescentsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 August 2022